Heather Raymon - 18 Jul 2024 Form 3 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Role
SVP, Research and Development
Signature
/s/ Jennifer Bush, Attorney-in-Fact
Issuer symbol
ARTV
Transactions as of
18 Jul 2024
Net transactions value
$0
Form type
3
Filing time
18 Jul 2024, 20:02:59 UTC
Next filing
13 Sep 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ARTV Employee Stock Option (Right to Buy) 18 Jul 2024 Common Stock 18,239 $5.14 Direct F1
holding ARTV Employee Stock Option (Right to Buy) 18 Jul 2024 Common Stock 12,539 $5.01 Direct F2
holding ARTV Employee Stock Option (Right to Buy) 18 Jul 2024 Common Stock 14,819 $5.01 Direct F3
holding ARTV Employee Stock Option (Right to Buy) 18 Jul 2024 Common Stock 11,399 $5.18 Direct F4
holding ARTV Employee Stock Option (Right to Buy) 18 Jul 2024 Common Stock 10,259 $13.47 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares vested on October 22, 2021, and the remaining shares vest in 36 equal monthly installments thereafter.
F2 25% of the shares vested on January 1, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.
F3 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
F4 Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts.
F5 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.